Activities of doripenem (S-4661) against drug-resistant clinical pathogens
Activities of doripenem (S-4661) against drug-resistant clinical pathogens
复制标题
DOI：
10.1128/aac.48.8.3136-3140.2004
复制
发表时间：
2004-08-01
影响因子：
4.9
通讯作者：
Biedenbach, DJ
中科院分区：
文献类型：
--
作者：
Jones, RN;Huynh, HK;Biedenbach, DJ
多利培南（以前称为S-4661）是一种新的1-β-甲基碳青霉烯类药物，使用全球收集的394株耐药分离株进行挑战。对于地方性产超广谱β-内酰胺酶和稳定去阻遏的产AmpC肠杆菌，多利培南对90%分离株的MIC（MIC（90）s）为0.03 - 0.5 μ g/ml，通常低于对照碳青霉烯类。在碳青霉烯类耐药非发酵革兰氏阴性杆菌中，多利培南在小于或等于4 μ g/ml时抑制较大比例的菌株，多利培南是对青霉素耐药链球菌最有效的碳青霉烯类（MIC 90，1 - 4 μ g/ml）。
Doripenem (formerly S-4661), a new 1-beta-methyl carbapenem, was challenged with a worldwide collection of 394 drug-refractory isolates. For endemic extended-spectrum beta-lactamase- and stably derepressed AmpC-producing enteric bacilli, the doripenem MICs at which 90% of the isolates were inhibited (MIC(90)s) were 0.03 to 0.5 mug/ml, generally lower than those of comparator carbapenems. A greater proportion of strains among carbapenem-resistant nonfermentative gram-negative bacilli were inhibited by doripenem at less than or equal to4 mug/ml, and doripenem was the most active carbapenem (MIC90, 1 to 4 mug/ml) against penicillin-resistant streptococci.